Drug intelligence / Profile preview

LIN-2005

Development stage: Preclinical
Lead developer: Linno Pharmaceuticals
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

LIN-2005 is a recombinant protein being developed by Linno Pharmaceuticals for the treatment of neuroinflammation following a stroke. The drug is designed to inhibit the complement system, a part of the innate immune response that can exacerbate brain tissue damage after an ischemic or hemorrhagic event. Linno Pharmaceuticals utilizes a proprietary blood-brain barrier (BBB) drug delivery platform to facilitate the penetration of this protein therapeutic into the central nervous system while minimizing potential neurotoxicity. As of early 2024, LIN-2005 is in the IND-enabling stage of preclinical development.

Targets

Complement (Complement system)

Beyond the preview

Go deeper on LIN-2005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIN-2005.

Explore the full profile